Updated just now · Live
Stock analysis, price data, and AI-powered insights for Passage Bio Inc (PASG).
Passage Bio Inc operates in the Biotechnology sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for PASG.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). PASG Stock Intelligence Report. [stoxpulse.com/stocks/pasg]
Disclaimer: The information on this page about Passage Bio Inc (PASG) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Passage Bio Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
This Mohawk Industries Analyst Is No Longer Bullis...
7h ago
Oppenheimer Maintains Outperform on Passage Bio, L...
7h ago
StoxPulse AI results for PASG: Pulse Score 49/100. Primary sentiment trends from 13 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$20.0M
P/E Ratio
—
EPS
$-2.44
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday
Oppenheimer Maintains Outperform on Passage Bio, Lowers Price Target to $15
Wedbush Downgrades Passage Bio to Neutral, Lowers Price Target to $8
Crude Oil Surges Over 6%; Investar Holding Shares Gain Following Q1 Earnings
12 Health Care Stocks Moving In Monday's Intraday Session
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results
Reported Earlier: Passage Bio Receives FDA Guidance Requiring Randomized Registrational Trial For PBFT02 in FTD-GRN, Evaluates Next Steps In Clinical Development
Passage Bio shares are trading lower after the company announced the FDA did not support a single-arm trial design for its indication in the Type C meeting and instead indicated that a randomized controlled trial would be required for registrational purposes. Also, the company announced it initiated a review of strategic alternatives to maximize shareholder value.